Frovex

Package leaflet: information for the user

FROVEX 2.5 mg film-coated tablets

Frovatriptan

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

What is in this leaflet:

1. What FROVEX is and what it is used for
2. What you need to know before you take FROVEX
3. How to take FROVEX
4. Possible side effects
5. How to store FROVEX
6. Contents of the pack and other information

1. What FROVEX is and what it is used for

FROVEX 2.5 mg tablets contain frovatriptan, an anti-migraine treatment belonging to the class of triptans (5-hydroxytryptamine (5HT1) selective receptor agonists).

FROVEX 2.5 mg tablets is a medicine for the treatment of the headache phase of a migraine attack with or without aura (a temporary strange feeling before a migraine, which varies from person to person but can affect, for example, vision, smell, hearing).

FROVEX 2.5 mg tablets should not be used to prevent a migraine attack.

FROVEX is used to treat migraine attacks in adults.

2. What you need to know before you take FROVEX

The diagnosis of migraine must have been clearly established by your doctor

Do not take FROVEX

Warning and precautions

Talk to your doctor before taking FROVEX

if you are a patient at risk of coronary artery disease, including if:

Stop taking FROVEX and talk to your doctor right away if you:

Children and adolescents

Do not give this medicine to children and adolescents (under 18 years of age) because the safety and efficacy of FROVEX have not been established in these groups.

Other medicines and FROVEX

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

You should not take this medicine at the same time as certain other medicines used for the treatment of migraine:

Unless otherwise directed by your doctor, you should not take this medicine at the same time as monoamine oxidase inhibitor (MAOI) medicines used in the treatment of depression (phenelzine, isocarboxazid, tranylcypromine, moclobemide).

It is recommended that you do not take FROVEX 2.5 mg tablets at the same time as taking St. John's Wort (hypericum perforatum).

Concomitant use of FROVEX with the medicines listed above (especially monoamine oxidase inhibitors, selective serotonin-reuptake inhibitors and hypericum perforatum) may also increase the risk of serotonin syndrome (the symptoms of serotonin syndrome include: shivering, sweating, agitation, trembling and abrubt contraction of muscles, nausea, fever, confusion).

If you have any doubt about taking other medicines with FROVEX 2.5 mg tablets, consult your doctor or pharmacist.

FROVEX with food and drink

FROVEX 2.5 mg tablets can be taken with food or on an empty stomach, always with an adequate amount of water.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

FROVEX 2.5 mg tablets should not be used during pregnancy or when breast feeding, unless you are told so by your doctor. In any case, you should not breastfeed for 24 hours after taking FROVEX and during this time any breast milk expressed should be discarded.

Driving and using machines

FROVEX 2.5 mg tablets and the migraine itself can cause drowsiness. If affected, driving or operating machinery can be dangerous and should be avoided.

FROVEX contains lactose

This product contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3. How to take FROVEX

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

Take FROVEX 2.5 mg tablets as early as possible after the onset of the migraine headache. Swallow one tablet whole with water.

If the first dose does not give you any relief, do not take a second dose during the same attack. You can use FROVEX 2.5 mg tablet for any following attacks.

If you obtain relief after the first dose, but later on suffer from the re-appearance of a headache within 24 hours, you can take a second dose provided that at least 2 hours have elapsed between the 2 doses.

Do not exceed the maximum dose of 5 mg (two tablets) in 24 hours.

Excessive use (repeated use over several consecutive days) of FROVEX 2.5 mg tablets constitutes incorrect use of this medicine and may cause an increase in side effects and lead to chronic daily headaches requiring the temporary discontinuation of treatment. Consult your doctor if you start having too frequent or daily headaches as you may be suffering from medication overuse headache.

Use in children and adolescents

FROVEX should not be used in patients under 18 years of age.

Elderly

As there is little experience in patients over 65 years, the use of FROVEX is not recommended in patients in this age group.

If you take more FROVEX than you should

If you accidentally take an overdose of this medicine, tell your doctor or pharmacist immediately or go to the emergency department of your nearest hospital. Please remember to take the remaining tablets or this leaflet with you.

If you stop taking FROVEX

No special precautions are necessary when stopping the drug.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking FROVEX and tell your doctor right away if you experience any of the following symptoms:

The side-effects reported with FROVEX 2.5 mg tablets were temporary, generally mild to moderate and disappeared spontaneously. Some symptoms reported may be caused by the migraine itself.

The following side-effects were commonly observed (estimated frequency is more than 1 person out of 100 and less than 1 person out of 10):

The following were uncommonly observed (estimated frequency is more than 1 person out of 1000 and less than 1 person out of 100):

The following were rare (estimated frequency is more than 1 person out of 10,000 and less than 1 person out of 1000):

Although the frequency cannot be estimated from the available data the following events were also reported:

Reporting of side effects

If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via

HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
E-mail: medsafety@hpra.ie

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store FROVEX

Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

Do not store above 30°C.

Blister: store in the original package in order to protect from moisture.

Bottle: keep the bottle tightly closed in order to protect from moisture.

Keep this medicine out of the sight and reach of children.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What FROVEX contains

The active substance is frovatriptan as succinate monohydrate.

Each tablet contains 2.5 mg of frovatriptan.

The other ingredients are:

Tablet core: anhydrous lactose, microcrystalline cellulose, magnesium stearate, sodium starch glycollate (type A), silica colloidal anhydrous.

Tablet coat: OPADRY white: titanium dioxide (E171), anhydrous lactose, hypromellose (E464), macrogol 3000, triacetin.

What FROVEX looks like and contents of the pack

FROVEX 2.5 mg film-coated tablets are available in the form of round film-coated tablets, debossed with "m" on one side and "2.5" on the other.

FROVEX is packed in:

Child-proof HDPE bottle: 30 tablets per each bottle

PVC/PE/ACLAR/Aluminium blister: 1, 2, 3, 4, 6 or 12 tablets per each blister

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare
L-1611, Luxembourg

Manufacturer:

Almac Pharma Services Limited
Almac House
20 Seagoe Industrial Estate
Craigavon
County Armagh
Northern Ireland
BT63 5UA
United Kingdom

or

Berlin-Chemie AG
Glienicker Weg 125
D-12489
Berlin
Germany

or

A.Menarini Manufacturing Logistics and services s.r.l.
Via Campo di Pile
L’Aquila (AQ)
Italy

or

Laboratorios Menarini S.A.
Alfonso XII, 587
08918 - Badalona
Barcelona
Spain

This medicinal product is authorised in the Member States of the EEA under the following names:

France (RMS) Tigreat

Austria Frovamig

Belgium Frovatex

Czech Republic Fromen

Germany Allegro

Greece Migralin

The Netherlands Fromirex

Hungary Frovalon

Iceland Tigreat

Ireland Frovex

Italy Auradol

Latvia Frovamig

Luxembourg Frovatex

Poland Migren

Portugal Dorlise

Slovakia Frovamen

Slovenia Frotan

Spain Perlic